GIS:ETR
Gilead Sciences, Inc
€118.90
arrow_downward
-0.02%(-0.020) 1D
Aug 14, 5:35:36 PM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GIS...
Open
€119.88
High
€119.88
Low
€117.86
Mkt. cap
171.56B
Avg. vol.
809.00
Volume
0.00
52-wk high
€132.00
52-wk low
€92.41
No. of employees
17K
Open
€119.88
High
€119.88
Low
€117.86
Mkt. cap
171.56B
Avg. vol.
809.00
Volume
0.00
52-wk high
€132.00
52-wk low
€92.41
No. of employees
17K
News stories
From web sources and news partners
Yahoo Finance
·
2 hours ago
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences, Inc
CEODaniel O'Day
Employees17K
FoundedJun 22, 1987
HeadquartersFoster City, California, United States
SectorBiotechnology
Websitegilead.com
AI content may include mistakes. Learn more